Definitive Hypofractionated Intensity-modulated Radiation Theraphy With Concurrent Chemotherapy in Cervical Cancer

Inclusion Criteria: * Histologically confirmed cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma) * FIGO stage IIB-IVA (2018) * Measurable primary tumor on pelvic MRI within 30 days prior to treatment initiation * Age ≥ 20 years * ECOG performance status 0-1 * Adequate bone marrow function: WBC ≥ 3,000/µL, ANC ≥ 1,000/µL, platelets ≥ 100,000/µL, hemoglobin ≥ 9 g/dL * Adequate renal function: Creatinine \< 2.0 mg/dL * Ability to provide written informed consent Exclusion Criteria: * Patients with distant metastasis * Patients who have previously received pelvic radiotherapy * Patients who have previously received definitive chemotherapy or chemoradiotherapy for diagnosed cervical cancer * Patients who have undergone surgery for the current cervical cancer lesion * Patients who underwent local excisional procedures of the cervix such as conization or Loop Electrosurgical Excision Procedure (LEEP) prior to radiotherapy * Patients who are unable to undergo concurrent chemoradiotherapy due to poor general condition * Patients with other active malignancies (except carcinoma in situ of the cervix, basal cell carcinoma of the skin, or superficial bladder cancer) within 3 years prior to enrollment or who experienced recurrence within 3 years after treatment